AcelRx Pharmaceuticals Company Profile (NASDAQ:ACRX)

AcelRx Pharmaceuticals trades on the NASDAQ under the ticker symbol "ACRX."

AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) issued its quarterly earnings data on Tuesday, August, 1st. The company reported ($0.29) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.28) by $0.01. The firm had revenue of $2.66 million for the quarter, compared to analyst estimates of $2.63 million. View AcelRx Pharmaceuticals' Earnings History.

AcelRx Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, October, 30th 2017. View Earnings Estimates for AcelRx Pharmaceuticals.

7 equities research analysts have issued twelve-month price targets for AcelRx Pharmaceuticals' shares. Their forecasts range from $2.00 to $14.00. On average, they anticipate AcelRx Pharmaceuticals' share price to reach $7.67 in the next twelve months. View Analyst Ratings for AcelRx Pharmaceuticals.

Here are some recent quotes from research analysts about AcelRx Pharmaceuticals stock:

• 1. According to Zacks Investment Research, "AcelRx Pharmaceuticals, Inc., is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of pain. The Company product candidates comprises: ARX-01 or the Sufentanil NanoTab PCA System; ARX-02 or the Sufentanil NanoTab BTP Management System; and ARX-03 or the Sufentanil/Triazolam NanoTab which are in their development stage. Its product ARX-01 is focused on acute post-operative pain, ARX-02 is focused on the treatment of cancer breakthrough pain and ARX-03 is focused on providing mild sedation, anxiety reduction, and pain relief to patients undergoing painful procedures in a physician's office. AcelRx Pharmaceuticals, Inc. is headquartered in Redwood City, California. " (8/4/2017)
• 2. Stifel Nicolaus analysts commented, "Arc Logistics Partners LP reported 4Q16 Adjusted EBITDA of $13.9 million, below our estimate of $14.9 million, and distributable cash flow (DCF) of $11.0 million against our estimate of $11.1 million. Adjusted EBITDA came in below our estimates due to slightly lower revenues and higher operating expense on the quarter. Management provided an update on the ongoing Gulf LNG arbitration case and noted that the arbitration panel has heard the arguments and is in the process of rendering a decision. With that said, a timeline for a decision was not provided. On the call management highlighted their belief that the Gulf arbitration is acting as an overhang on ARCX units and expect a resolution to provide uplift to the partnership's valuation (assuming a positive outcome). Although we ultimately expect a favorable resolution for ARCX in the Gulf LNG arbitration, a full valuation and uncertainty over the outcome are keeping us on the sidelines. At this time we are maintaining our Hold rating." (3/14/2017)
• 3. Royal Bank Of Canada analysts commented, "ACRX reported 4Q results after the close where focus was primarily on the upcoming DSUVIA (ARX-04) launch, the expected AdCom meeting prior to approval, and progress with the Zalviso trial and the EU launch. We continue to view the story as on-track and make only minor adjustments to our model. We reiterate our Outperform rating and $6 PT." (3/3/2017)

Some companies that are related to AcelRx Pharmaceuticals include Sorrento Therapeutics (SRNE), Fate Therapeutics (FATE), Ovid Therapeutc (OVID), Recro Pharma (REPH), Vascular Biogenics (VBLT), Redhill Biopharma (RDHL), Synthetic Biologics (SYN), Conatus Pharmaceuticals (CNAT), Dimension Therapeutics (DMTX), XBiotech (XBIT), Adverum Biotechnologies (ADVM), Agile Therapeutics (AGRX), Verastem (VSTM), Cempra (CEMP), Summit Therapeutics PLC (SMMT), Immune Design Corp. (IMDZ), Cellular Biomedicine Group (CBMG) and Cidara Therapeutics (CDTX).

AcelRx Pharmaceuticals' management team includes the folowing people:

• Adrian Adams, Independent Chairman of the Board
• Richard A. King, President
• Vincent J. Angotti, Chief Executive Officer
• Raffi M. Asadorian, Chief Financial Officer
• Pamela P. Palmer M.D. Ph.D., Chief Medical Officer, Director
• Badri N. Dasu, Chief Engineering Officer
• Lawrence G. Hamel, Chief Development Officer
• Jane Wright-Mitchell, Chief Legal Officer
• Richard F. Afable M.D., Director
• Howard B. Rosen, Director

Shares of AcelRx Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of AcelRx Pharmaceuticals stock can currently be purchased for approximately $2.03.